The estimated Net Worth of John M. Evans is at least 47.9 百万$ dollars as of 27 June 2024. Mr. Evans owns over 60,000 units of Beam Therapeutics stock worth over 24,080,033$ and over the last 4 years he sold BEAM stock worth over 21,566,385$. In addition, he makes 2,209,800$ as Chief Executive Officer、 Director at Beam Therapeutics.
Sign up
Mr. Evans BEAM stock SEC Form 4 insiders trading
John has made over 16 trades of the Beam Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 60,000 units of BEAM stock worth 1,470,000$ on 27 June 2024.
The largest trade he's ever made was exercising 115,000 units of Beam Therapeutics stock on 16 April 2020 worth over 118,450$. On average, John trades about 33,911 units every 81 days since 2020. As of 27 June 2024 he still owns at least 998,343 units of Beam Therapeutics stock.
You can see the complete history of Mr. Evans stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Evans biography
John M. Evans serves as Chief Executive Officer, Director of the Company. Mr. Evans has significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans has also served as a Venture Partner with ARCH Venture Partners since 2017 and as a Director of Verve Therapeutics since August 2018. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, from September 2009 until April 2017, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA and TIBSOVO. He helped initiate and lead Agios’ landmark alliance with Celgene, resulting in over $600 million of funding and investments across multiple research collaborations in cancer metabolism. At Agios, Mr. Evans led a team of eight employees. He also co-led Agio’s expansion into rare genetic diseases. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company’s pharmaceuticals practice and MedImmune. Mr. Evans holds an MBA in Healthcare Management from Wharton, a M.S. in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.
What is the salary of John Evans?
As the Chief Executive Officer、 Director of Beam Therapeutics, the total compensation of John Evans at Beam Therapeutics is 2,209,800$. There are 1 executives at Beam Therapeutics getting paid more, with Terry-Ann Burrell having the highest compensation of 4,302,720$.
How old is John Evans?
John Evans is 42, he's been the Chief Executive Officer、 Director of Beam Therapeutics since 2020. There are 14 older and 1 younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics Inc. is Mark Fishman, 68, who is the Independent Director.
What's John Evans's mailing address?
John's mailing address filed with the SEC is C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE, MA, 02142.
Insiders trading at Beam Therapeutics
Over the last 5 years, insiders at Beam Therapeutics have traded over 63,012,019$ worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red...、Llc Fmr、Kristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of 1,019,987$. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth 29,100$.
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
What does Beam Therapeutics's logo look like?
Complete history of Mr. Evans stock trades at Beam Therapeutics
Beam Therapeutics executives and stock owners
Beam Therapeutics executives and other stock owners filed with the SEC include:
-
Terry-Ann Burrell,
Chief Financial Officer, Treasurer -
John Evans,
Chief Executive Officer, Director -
Giuseppe Ciaramella,
President, Chief Scientific Officer -
John M. Evans M.B.A.,
CEO & Director -
Dr. Giuseppe Ciaramella Ph.D.,
Pres & Chief Scientific Officer -
Terry-Ann Burrell M.B.A.,
CFO & Treasurer -
Carole Ho,
Independent Director -
Mark Fishman,
Independent Director -
Graham Cooper,
Independent Director -
Robert Nelsen,
Independent Director -
Stephen Knight,
Independent Director -
Kristina Burow,
Independent Director -
Christine Swenson,
Senior Vice President - Regulatory Affairs -
Manmohan Singh,
Senior Vice President - Pharmaceutical Sciences and Delivery Technology -
David Liu,
Co-Founder -
J. Keith Joung,
Co-Founder -
Dr. Alexis Komor Ph.D.,
Co-Founder -
Dr. Nicole Gaudelli Ph.D.,
Co-Founder -
Suzanne Fleming,
Chief Accounting Officer -
Dr. J. Keith Joung M.D., Ph.D.,
Co-Founder -
Courtney Wallace,
Chief Bus. Officer -
Susan O'Connor,
Chief HR Officer -
Dr. Christine P. Bellon J.D., Ph.D.,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Brian Riley,
Sr. VP of Technical Operations -
Dr. Feng Zhang,
Co-Founder -
John Maraganore,
-
Kathleen E Walsh,
-
Bethany J Cavanagh,
SVP, Finance and Treasurer -
Group, Llc Green Jeremy Red...,
-
Venture Partners Ix, Llcarc...,
-
Venture Partners Ix, Llcarc...,
-
Llc Fmr,
-
Amy Simon,
Chief Medical Officer -
Christine Bellon,
Chief Legal Officer -
Christi Shaw,